Back to results

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

Primary Purpose

B-cell Lymphoma

Status

Completed

Phase

Phase 1

Locations

China

Study Type

Interventional

Intervention

Zanubrutinib

About this trial

This is an interventional treatment trial for B-cell Lymphoma

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

Men and women between the age of 18-75 years.
Participants with B-cell lymphoma (defined by World Health Organization classification) refractory or relapsed following at least one line of therapy.
Judged by the investigator as requiring treatment.
Eastern Cooperative Oncology Group performance status of 0-1.
Life expectancy of at least 4 months.
Adequate hematological function.
Adequate renal function.
Adequate liver function.
Adequate coagulation function.
Female participants of childbearing potential and non-sterile males must have practiced at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drug.
Male participants must not have donated sperm from start of study drug administration, until 90 days after discontinuation of treatment.

Key Exclusion Criteria:

With central nervous system involvement of the disease.
The pathological type of the disease had disease transformation.
Had underdone allogeneic hematopoietic stem cell transplantation.
Had received corticosteroid anti-neoplastic treatment within 7 days before the first dose, has received radiotherapy and chemotherapy within 4 weeks before the first dose or has received treatment with monoclonal antibody within 4 weeks before the first dose.
Had received BTK inhibitor treatment prior to enrollment.
Had received chemotherapy and has not yet recovered from toxicity
Had received Chinese herbal medicine as anti-neoplastic therapy within 4 weeks before starting study treatment.
History of other malignancies within 2 years before study.
With uncontrolled systemic infection.
Major surgery in the past 4 weeks.
With known HIV, or active hepatitis B or hepatitis C virus infection.
With cardiovascular disease of New York Heart Association Classification ≥ 3.
Significant electrocardiogram abnormalities.
Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participation in the study.
Inability to comply with study procedures.
Was currently taking anticoagulant drugs.
Was currently taking potent cytochrome P450 3A inhibitor or inducer.
Had stroke or cerebral hemorrhage within 6 months before enrollment.

Note: Other protocol defined Inclusion/Exclusion criteria may have applied.

Sites / Locations

Beijing Cancer Hospital
Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology
Jiangsu Province Hospital
Tianjin Hematonosis Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Arm Label

Part I: 160 mg BID

Part I: 320 mg QD

Part II: 160 mg BID

Arm Description

Safety Evaluation: Two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily [BID]) administered in the morning and at night, or 320 mg (once daily [QD]), and a "3+3" design was adopted for Part I of the study to determine recommended Phase 2 dose (RP2D).

Safety Evaluation: Two regimens of zanubrutinib 320 mg daily (160 mg BID, administered in the morning and at night, or 320 mg QD) and a "3+3" design was adopted for Part I of the study to determine RP2D.

Dose Expansion: The RP2D determined in Part I was used in Part II to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Outcomes

Primary Outcome Measures

Part I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

All adverse events were treatment emergent and were defined as an adverse event with a reported onset time or increase in severity after the initial dose of study drug and within 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever was sooner. A serious adverse event was any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is significant medical event requiring intervention. All toxicity and adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03 (NCI-CTCAE v4.03) grading criteria. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Part II: Overall Response Rate (ORR) Of Zanubrutinib In Participants With FL And MZL

Overall response in overall response rate (ORR) was defined as a participant's best overall response: CR or PR for NHL participants; CR, complete remission with incomplete blood count recovery, nodular PR, PR, or PR with lymphocytosis for the CLL participants; CR, very good PR, PR, or minor response for the Waldenström macroglobulinemia participants. ORR was defined as the percentage of participants who achieved an overall response.

Part II: Complete Response Rate (CRR) Of Zanubrutinib In Participants With FL And MZL

CRR was defined as the percentage of participants who achieved CR as the best overall response.

Part II: Partial Response Rate (PRR) Of Zanubrutinib In Participants With FL And MZL

PRR was defined as the percentage of participants who achieved PR or higher as the best overall response.

Part II: Duration of Response (DOR) Of Zanubrutinib In Participants With FL And MZL

Duration of response for responders (those who achieved an overall response of PR or better) was defined as the time interval (in number of days) between the date of the earliest qualifying response and the date of progressive disease or death for any cause (whichever occurs earlier). Duration of response analysis included only responders.

Part II: Progression Free Survival (PFS) Of Zanubrutinib In Participants With FL And MZL

Progression-free survival was defined as the time (in months) from the date of first study treatment to disease progression or death (due to any cause), whichever occurred first. For purposes of calculating PFS, the start date of progressive disease was the date at which progression was first observed. The duration and primary analysis of PFS was right-censored for participants who met 1 of the following conditions: 1) no baseline disease assessments; 2) starting a new anticancer therapy before documentation of disease progression or death; 3) death or disease progression immediately after more than 1 consecutively missed disease assessment visit; and 4) alive without documentation of disease progression before the data cutoff date.

Secondary Outcome Measures

Part I and Part II: Area Under The Plasma Concentration-time Curve From Zero To The Last Measurable Concentration (AUClast) For Single-dose Zanubrutinib

Part I and Part II: Area Under The Plasma Concentration-time Curve Zero To Infinity (AUC0-inf) For Single-dose Zanubrutinib

Part I And Part II: Maximum Plasma Concentration (Cmax) For Single-dose Zanubrutinib

Part I and Part II: Time To Maximum Plasma Concentration (Tmax) For Single-dose Zanubrutinib

Part I and Part II: Apparent Terminal Half Life (t1/2) For Single-dose Zanubrutinib

Part I and Part II: Apparent Plasma Clearance (CL/F) For Single-dose Zanubrutinib

Part I and Part II: Terminal Apparent Volume Of Distribution (Vz/F) For Single-dose Zanubrutinib

Part I and Part II: Area Under The Plasma Concentration-time Curve For Steady State (AUCss) Zanubrutinib

Part I and Part II: Maximum Plasma Concentration At Steady State (Cmax,ss) For Zanubrutinib

Part I and Part II: Time To Steady Plasma Concentration (Tmax,ss) For Zanubrutinib

Part I: Percentage of BTK Occupied In Peripheral Blood Mononuclear Cells In Participants Who Received Zanubrutinib

The percentage of BTK occupied in peripheral blood mononuclear cells was evaluated as a biomarker for the inhibition of BTK on specified days and the average value is reported.

Part II: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

All adverse events are treatment emergent, defined as an adverse event with a reported onset time or increase in severity after the initial dose of study drug and within 30 days after the last dose of study drug or initiation of new anticancer therapy, whichever was sooner. A serious adverse event was any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is significant medical event requiring intervention. All toxicity and adverse events were assessed according to the NCI-CTCAE v4.03 grading criteria. A summary of serious and all other non-serious adverse events, regardless of causality, is located in the Reported Adverse Events module.

Full Information

NCT ID

NCT03189524

First Posted

June 13, 2017

Last Updated

September 26, 2021

Sponsor

BeiGene

1. Study Identification

Unique Protocol Identification Number

NCT03189524

Brief Title

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

Official Title

A Phase I Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma

Study Type

Interventional

2. Study Status

Record Verification Date

September 2021

Overall Recruitment Status

Completed

Study Start Date

July 5, 2016 (Actual)

Primary Completion Date

August 26, 2020 (Actual)

Study Completion Date

August 26, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

BeiGene

4. Oversight

5. Study Description

Brief Summary

This phase I clinical study was to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in Chinese participants with B-cell lymphoma by conducting in two stages, the first stage being the safety assessment of dose and the second stage being the dose expansion. Part I: Safety evaluation - according to the results of preclinical toxicological trials and the results of the phase I clinical study conducted in Australia and New Zealand, two regimens of zanubrutinib 320 milligrams (mg) daily (160 mg twice daily [BID]), administered in the morning and at night, or 320 mg once daily [QD]) and "3+3" design was adopted for the assessment. The recommended dose and method of administration of the phase II clinical study was determined according to the Part I results. Part II: Dose expansion - this stage was to further evaluate the preliminary anti-tumor effects of zanubrutinib in Chinese participants with follicular lymphoma (FL) or marginal zone lymphoma (MZL), approximately 20 participants with relapsed or refractory FL or MZL were to be enrolled. The recommended Phase 2 dose (RP2D) was used in Part II.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

B-cell Lymphoma

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

44 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Part I: 160 mg BID

Arm Type

Experimental

Arm Description

Arm Title

Part I: 320 mg QD

Arm Type

Experimental

Arm Description

Arm Title

Part II: 160 mg BID

Arm Type

Experimental

Arm Description

Intervention Type

Drug

Intervention Name(s)

Zanubrutinib

Other Intervention Name(s)

BGB-3111

Intervention Description

Zanubrutinib is a white to off-white solid that is slightly hygroscopic. The drug product was formulated as 20-mg (blue, size 3) and 80-mg (white, size 0) hard gelatin, opaque oral capsules. Zanubrutinib is classified as a Biopharmaceutics Classification System Class II compound.

Primary Outcome Measure Information:

Title

Part I: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

Description

Time Frame

From the date of informed consent until 30 +/- 7 days after treatment discontinuation (up to 4 years and 1 month)

Title

Part II: Overall Response Rate (ORR) Of Zanubrutinib In Participants With FL And MZL

Description

Time Frame

Up to 4 years and 1 month

Title

Part II: Complete Response Rate (CRR) Of Zanubrutinib In Participants With FL And MZL

Description

CRR was defined as the percentage of participants who achieved CR as the best overall response.

Time Frame

Up to 4 years and 1 month

Title

Part II: Partial Response Rate (PRR) Of Zanubrutinib In Participants With FL And MZL

Description

PRR was defined as the percentage of participants who achieved PR or higher as the best overall response.

Time Frame

Up to 4 years and 1 month

Title

Part II: Duration of Response (DOR) Of Zanubrutinib In Participants With FL And MZL

Description

Time Frame

Up to 4 years and 1 month

Title

Part II: Progression Free Survival (PFS) Of Zanubrutinib In Participants With FL And MZL

Description

Time Frame

Up to 4 years and 1 month

Secondary Outcome Measure Information:

Title

Part I and Part II: Area Under The Plasma Concentration-time Curve From Zero To The Last Measurable Concentration (AUClast) For Single-dose Zanubrutinib

Time Frame

Part 1 and 2 : Week 1 day1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, 12 and 24 hours, and Week 2-day 1 Pre-dose, 0.5, 1, 2, 3, 4, 6 (part2 only), 8, and 12 hours (part2 only), and Week 5 and Week 9 Day 1 Pre-dose

Title

Part I and Part II: Area Under The Plasma Concentration-time Curve Zero To Infinity (AUC0-inf) For Single-dose Zanubrutinib

Time Frame

Title

Part I And Part II: Maximum Plasma Concentration (Cmax) For Single-dose Zanubrutinib

Time Frame

Title

Part I and Part II: Time To Maximum Plasma Concentration (Tmax) For Single-dose Zanubrutinib

Time Frame

Title

Part I and Part II: Apparent Terminal Half Life (t1/2) For Single-dose Zanubrutinib

Time Frame

Title

Part I and Part II: Apparent Plasma Clearance (CL/F) For Single-dose Zanubrutinib

Time Frame

Title

Part I and Part II: Terminal Apparent Volume Of Distribution (Vz/F) For Single-dose Zanubrutinib

Time Frame

Title

Part I and Part II: Area Under The Plasma Concentration-time Curve For Steady State (AUCss) Zanubrutinib

Time Frame

Title

Part I and Part II: Maximum Plasma Concentration At Steady State (Cmax,ss) For Zanubrutinib

Time Frame

Title

Part I and Part II: Time To Steady Plasma Concentration (Tmax,ss) For Zanubrutinib

Time Frame

Title

Part I: Percentage of BTK Occupied In Peripheral Blood Mononuclear Cells In Participants Who Received Zanubrutinib

Description

The percentage of BTK occupied in peripheral blood mononuclear cells was evaluated as a biomarker for the inhibition of BTK on specified days and the average value is reported.

Time Frame

DLT Period: Days 1 and 2 of Week 1 and Day 1 of Week 2

Title

Part II: Number Of Participants Experiencing Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events

Description

Time Frame

From the date of informed consent until 30 +/- 7 days after treatment discontinuation (up to 4 years and 1 month)

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

75 Years

Accepts Healthy Volunteers

Eligibility Criteria

Key Inclusion Criteria: Men and women between the age of 18-75 years. Participants with B-cell lymphoma (defined by World Health Organization classification) refractory or relapsed following at least one line of therapy. Judged by the investigator as requiring treatment. Eastern Cooperative Oncology Group performance status of 0-1. Life expectancy of at least 4 months. Adequate hematological function. Adequate renal function. Adequate liver function. Adequate coagulation function. Female participants of childbearing potential and non-sterile males must have practiced at least one of the following methods of birth control with partner(s) throughout the study and for 90 days after discontinuing study drug: total abstinence from sexual intercourse, double-barrier contraception, intrauterine device or hormonal contraceptive initiated at least 3 months prior to first dose of study drug. Male participants must not have donated sperm from start of study drug administration, until 90 days after discontinuation of treatment. Key Exclusion Criteria: With central nervous system involvement of the disease. The pathological type of the disease had disease transformation. Had underdone allogeneic hematopoietic stem cell transplantation. Had received corticosteroid anti-neoplastic treatment within 7 days before the first dose, has received radiotherapy and chemotherapy within 4 weeks before the first dose or has received treatment with monoclonal antibody within 4 weeks before the first dose. Had received BTK inhibitor treatment prior to enrollment. Had received chemotherapy and has not yet recovered from toxicity Had received Chinese herbal medicine as anti-neoplastic therapy within 4 weeks before starting study treatment. History of other malignancies within 2 years before study. With uncontrolled systemic infection. Major surgery in the past 4 weeks. With known HIV, or active hepatitis B or hepatitis C virus infection. With cardiovascular disease of New York Heart Association Classification ≥ 3. Significant electrocardiogram abnormalities. Significant active renal, neurologic, psychiatric, hepatic or endocrinologic disease that in the investigator's opinion would adversely impact on his/her participation in the study. Inability to comply with study procedures. Was currently taking anticoagulant drugs. Was currently taking potent cytochrome P450 3A inhibitor or inducer. Had stroke or cerebral hemorrhage within 6 months before enrollment. Note: Other protocol defined Inclusion/Exclusion criteria may have applied.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Study Director

Organizational Affiliation

BeiGene

Official's Role

Principal Investigator

Facility Information:

Facility Name

Beijing Cancer Hospital

City

Beijing

State/Province

Beijing

ZIP/Postal Code

100142

Country

China

Facility Name

Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology

City

Wuhan

State/Province

Hubei

Country

China

Facility Name

Jiangsu Province Hospital

City

Nanjing

State/Province

Jiangsu

Country

China

Facility Name

Tianjin Hematonosis Hospital

City

Tianjin

State/Province

Tianjin

Country

China

12. IPD Sharing Statement

Plan to Share IPD

Yes

Citations:

Citation

Jun Zhu, BS, Jianyong Li, MD, Jianfeng Zhou, Yuqin Song, MD, Junyuan Qi, Wei Xu, Dengju Li, MD, Mingyuan Sun, Ling Xue, PhD, Liudi Yang, Yinwei Zhang, Lai Wang, PhD, Jane Huang, MD, Shibao Feng, PhD, Lugui Qiu, MD. BGB-3111, a Highly Specific BTK Inhibitor, Is Well Tolerated and Highly Active in Chinese Patients with Relapsed/Refractory B-Cell Malignancies: Initial Report of a Phase 1 Trial in China. Blood. 2017; 130(1): 5347. https://doi.org/10.1182/blood.V130.Suppl_1.5347.5347

Results Reference

background

PubMed Identifier

35900694

Citation

Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. Adv Ther. 2022 Sep;39(9):4250-4265. doi: 10.1007/s12325-022-02238-7. Epub 2022 Jul 28.

Results Reference

derived

PubMed Identifier

35383885

Citation

Song Y, Sun M, Qi J, Xu W, Zhou J, Li D, Li J, Qiu L, Du C, Guo H, Huang J, Tang Z, Ou Y, Wu B, Yu Y, Zhu J. A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies. Br J Haematol. 2022 Jul;198(1):62-72. doi: 10.1111/bjh.18162. Epub 2022 Apr 5.

Results Reference

derived

Learn more about this trial

A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma

We'll reach out to this number within 24 hrs